Acetyl-Carnosine: Mechanism, Dosing & Research Data

Acetyl-carnosine (N-acetylcarnosine, NAC) is the acetylated prodrug form of carnosine (beta-Ala-His), developed by Mark Babizhayev for ophthalmic use. When applied as eye drops, NAC penetrates corneal epithelium and is hydrolyzed intracellularly to carnosine, which then functions as a potent antioxidant, protein carbonyl scavenger, and glycation inhibitor specifically within the lens. The primary application is prevention and reversal of nuclear cataracts.

Mechanism of Action

Hydrolyzed to carnosine by corneal esterases after penetrating corneal epithelium; carnosine cannot penetrate intact cornea due to charge, hence prodrug requirement
Carnosine scavenges reactive oxygen species (superoxide, hydroxyl radical, singlet oxygen) and reactive carbonyl compounds from lipid peroxidation
Inhibits glycation of lens crystallin proteins by acting as a competitive substrate for AGE (advanced glycation end-product) formation; reduces nuclear lens protein aggregation
Transglycation: carnosine reverses early-stage glycated protein adducts by accepting the glycating sugar moiety from lens proteins (deglycation activity)
In systemic nootropic use: oral NAC may release some carnosine systemically, providing muscle and brain carnosine levels; however GI carnosinase degrades most carnosine before absorption

Research Findings

Russian clinical study (Babizhayev): 1% NAC eye drops twice daily for 6 months improved visual acuity in 90% of cataract patients with early/intermediate nuclear cataract vs 0% improvement with placebo
Randomized controlled trial (Can-C drops): 1% NAC showed statistically significant improvement in lens optical density by retroillumination photography after 24 months
US ophthalmology skepticism: several Western reviews question study quality and reproducibility; NAC for cataracts remains controversial in mainstream ophthalmology despite biologically plausible mechanism
Animal models: NAC eye drops prevented selenite-induced nuclear cataract in rats and dogs when applied prophylactically
Nootropic claim (oral): preliminary data suggests oral NAC at 400-1000 mg/day modestly raises plasma carnosine; brain carnosine effects require further study

Research Protocols

Ophthalmic: 1-2 drops 1% NAC solution (Can-C, OcuSense) each eye twice daily; evaluate at 3-month intervals by slit-lamp and visual acuity
Prevention: 1 drop 1% NAC twice daily in high-risk patients (diabetics, high UV exposure) as prophylaxis
Oral nootropic: 400-1000 mg NAC daily orally; limited evidence; carnosine itself may be preferable at 1-2 g/day for systemic effects
Combination: some protocols combine oral carnosine (1-2 g/day) + ophthalmic NAC (1%) for concurrent systemic and local effects

Interactions

Carnosine (oral): related compound; carnosine better for systemic use; NAC better for ophthalmic use due to corneal penetration advantage
Antioxidants (Vitamin C, E): theoretically complementary for oxidative lens protection; no formal interaction studies
Antiglaucoma eye drops: no known pharmacological interaction; can be co-administered at different times

Safety Profile

Excellent ocular and systemic safety profile. No significant side effects in studies. Mild transient stinging upon instillation reported by some users. No systemic absorption of clinical concern from ophthalmic application. Oral NAC well tolerated. Not FDA-approved as drug but sold OTC as supplement.